Gilead Reports Second Interim P-III (TROPiCS-02) Study Results of Trodelvy (sacituzumab govitecan-hziy) for HR+/HER2- Metastatic Breast Cancer
- The P-III (TROPiCS-02) study evaluating Trodelvy vs CT (eribulin, capecitabine, gemcitabine, or vinorelbine) in a ratio (1:1) in 543 patients with HR+/HER2- metastatic breast cancer with HER2-low & IHC 0 status prior treated with endocrine therapy, CDK4/6 inhibitors & two to four lines of CT
- The results showed an improvement in OS & the safety profile was consistent with prior studies with no new safety signals. The results will be presented at an upcoming medical conference
- The company has submitted an sBLA of Trodelvy to the US FDA & the results will also be shared with health authorities outside the US. The therapy is also being studied for other TNBC & metastatic UC populations along with a range of tumor types
Ref: Gilead Sciences, Inc. | Image: Gilead Sciences, Inc.
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.